| Liposomal formulations in clinical use: an updated review U Bulbake, S Doppalapudi, N Kommineni, W Khan Pharmaceutics 9 (2), 12, 2017 | 1979 | 2017 |
| Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis M Walunj, S Doppalapudi, U Bulbake, W Khan Journal of liposome research 30 (1), 68-79, 2020 | 95 | 2020 |
| Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis A Jain, V Pooladanda, U Bulbake, S Doppalapudi, TA Rafeeqi, C Godugu, ... Nanomedicine: Nanotechnology, Biology and Medicine 13 (7), 2251-2262, 2017 | 85 | 2017 |
| Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer N Kommineni, R Saka, U Bulbake, W Khan Chemistry and physics of lipids 224, 104707, 2019 | 45 | 2019 |
| Chitosan sponges as a sustained release carrier system for the prophylaxis of orthopedic implant-associated infections V Pawar, U Bulbake, W Khan, R Srivastava International journal of biological macromolecules 134, 100-112, 2019 | 35 | 2019 |
| Liposomal formulations in clinical use: An updated review. Pharmaceutics, 9 (2), 1–33 U Bulbake, S Doppalapudi, N Kommineni, W Khan | 28 | 2017 |
| Preparation and comparison of oral bioavailability for different nano-formulations of olaparib AD Pathade, N Kommineni, U Bulbake, MM Thummar, G Samanthula, ... AAPS PharmSciTech 20, 1-13, 2019 | 27 | 2019 |
| Liposomal formulations in clinical use: an updated review, Pharmaceutics 9 (2017) 12 U Bulbake, S Doppalapudi, N Kommineni, W Khan, U Bulbake, ... DOI, 2016 | 21 | 2016 |
| Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 2017, 9, 12 U Bulbake, S Doppalapudi, N Kommineni, W Khan DOI 10, 3390, 0 | 21 | |
| Cationic liposomes for co-delivery of paclitaxel and anti-Plk1 siRNA to achieve enhanced efficacy in breast cancer U Bulbake, N Kommineni, M Bryszewska, M Ionov, W Khan Journal of Drug Delivery Science and Technology 48, 253-265, 2018 | 19 | 2018 |
| Comparison of cationic liposome and PAMAM dendrimer for delivery of anti-Plk1 siRNA in breast cancer treatment U Bulbake, N Kommineni, M Ionov, M Bryszewska, W Khan Pharmaceutical development and technology 25 (1), 9-19, 2020 | 15 | 2020 |
| Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products M Thummar, BS Kuswah, G Samanthula, U Bulbake, J Gour, W Khan Journal of Pharmaceutical and Biomedical Analysis 160, 89-98, 2018 | 13 | 2018 |
| Curcumin loaded biomimetic composite graft for faster regeneration of skin in diabetic wounds U Bulbake, S Jain, N Kumar, A Mittal Journal of Drug Delivery Science and Technology 47, 12-21, 2018 | 12 | 2018 |
| Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017; 9 (2): 1–33 U Bulbake, S Doppalapudi, N Kommineni, W Khan | 8 | |
| Therapeutic macromolecular iron chelators U Bulbake, A Singh, AJ Domb, W Khan Current Medicinal Chemistry 26 (2), 323-334, 2019 | 7 | 2019 |
| Liposomal drug delivery system and its clinically available products U Bulbake, N Kommineni, W Khan Handbook of Materials for Nanomedicine, 121-172, 2020 | 5 | 2020 |
| Nanotherapeutics: Emerging trends in management of psoriasis S Doppalapudi, A Jain, U Bulbake, W Khan Pharmaceutical Nanotechnology 4 (4), 267-283, 2016 | 4 | 2016 |
| Nanocarriers as Non-Viral Vectors in Gene Delivery Application U Bulbake, A Jain, W Khan Multifunctional Nanocarriers for Contemporary Healthcare Applications, 357-380, 2018 | 1 | 2018 |
| Chitin–and Chitosan‐Based Scaffolds U Bulbake, S Doppalapudi, W Khan Chitosan: Derivatives, Composites and Applications, 271-310, 2017 | 1 | 2017 |
Wahid KhanNATCO PharmaVerified email at natcopharma.co.in
